NeuroSense Therapeutics (NASDAQ:NRSN) Earns Buy Rating from D. Boral Capital

NeuroSense Therapeutics (NASDAQ:NRSN)‘s stock had its “buy” rating restated by equities research analysts at D. Boral Capital in a report released on Monday,Benzinga reports. They presently have a $14.00 target price on the stock.

Other equities research analysts have also recently issued reports about the company. Zacks Research upgraded NeuroSense Therapeutics to a “hold” rating in a research note on Wednesday, October 15th. Noble Financial raised shares of NeuroSense Therapeutics to a “strong-buy” rating in a report on Tuesday, October 14th. Wall Street Zen lowered shares of NeuroSense Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, December 13th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of NeuroSense Therapeutics in a research note on Monday, December 8th. Two research analysts have rated the stock with a Strong Buy rating, one has issued a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, NeuroSense Therapeutics presently has an average rating of “Moderate Buy” and an average price target of $14.00.

NeuroSense Therapeutics Stock Performance

NASDAQ:NRSN opened at $0.84 on Monday. NeuroSense Therapeutics has a 12-month low of $0.76 and a 12-month high of $2.60. The business has a 50 day simple moving average of $1.05 and a 200 day simple moving average of $1.39.

Institutional Trading of NeuroSense Therapeutics

Several institutional investors have recently modified their holdings of NRSN. Two Sigma Investments LP bought a new stake in shares of NeuroSense Therapeutics in the 3rd quarter worth approximately $26,000. Squarepoint Ops LLC increased its holdings in shares of NeuroSense Therapeutics by 91.0% in the third quarter. Squarepoint Ops LLC now owns 95,375 shares of the company’s stock valued at $119,000 after buying an additional 45,450 shares in the last quarter. Finally, Jane Street Group LLC bought a new stake in shares of NeuroSense Therapeutics during the 2nd quarter worth $54,000. Institutional investors and hedge funds own 1.04% of the company’s stock.

NeuroSense Therapeutics Company Profile

NeuroSense Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies for neurodegenerative and age-related neurological disorders. The company’s primary mission is to address unmet medical needs in diseases characterized by protein aggregation, chronic inflammation and cellular senescence in the central nervous system.

At the core of NeuroSense’s approach is a proprietary senotherapeutic platform designed to selectively target and clear senescent cells that contribute to neurodegeneration.